Compare
Upstream Bio, Inc. vs Cartesian Therapeutics, Inc. vs GeoVax Labs, Inc. vs Camp4 Therapeutics Corp
| Latest fiscal year | Upstream Bio, Inc. UPB | Cartesian Therapeutics, Inc. RNAC | GeoVax Labs, Inc. GOVX | Camp4 Therapeutics Corp CAMP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $2.85M | $2.80M | $2.49M | $3.50M |
| Revenue growth (YoY) | +20.4% | -92.8% | -37.1% | +436.5% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | -869.3% | n/m |
| Net margin | n/m | n/m | -862.3% | n/m |
| Net income | -$143.44M | -$130.30M | -$21.46M | -$80.40M |
| EPS (Diluted) | -$2.66 | -$5.02 | n/a | -$2.65 |
| Operating cash flow | -$133.28M | -$73.94M | -$21.47M | -$29.55M |
| Free cash flow | -$133.44M | -$79.39M | -$21.50M | -$29.83M |
| Cash & equivalents | $101.58M | $125.14M | $3.09M | $109.52M |
| Total assets | $353.77M | $296.41M | $6.34M | $117.81M |
| Total liabilities | $14.00M | $422.65M | $2.52M | $70.10M |
| Shareholders' equity | $339.77M | -$126.24M | $3.83M | $47.70M |
| Return on year-end equity | -42.2% | n/a | -561.2% | -168.5% |
| Shares outstanding | 54.24M | 26.01M | 1.73M | 51.90M |
Revenue, most recent five fiscal years
| Fiscal year | Upstream Bio, Inc. | Cartesian Therapeutics, Inc. | GeoVax Labs, Inc. | Camp4 Therapeutics Corp |
|---|---|---|---|---|
| Latest | $2.85M Ended 2025-12-31 | $2.80M Ended 2025-12-31 | $2.49M Ended 2025-12-31 | $3.50M Ended 2025-12-31 |
| 1 year earlier | $2.37M Ended 2024-12-31 | $38.91M Ended 2024-12-31 | $3.95M Ended 2024-12-31 | $652.0K Ended 2024-12-31 |
| 2 years earlier | $2.38M Ended 2023-12-31 | $26.00M Ended 2023-12-31 | $0 Ended 2023-12-31 | $350.0K Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $81.5K Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | n/a | $385.5K Ended 2021-12-31 | n/a |